FDA Grants AstaPure - Astaxanthin Structural Health Claims

Oct. 27, 2009
Algatechnologies, Israel, announced that the FDA reviewed and is allowing the use of 12 new structural health claims filed for its AstaPure brand of natural astaxanthin in the US market.For more than 10 years, astaxanthin’s role in enhancing the immune system and preventing oxidative stress has been the subject of international research both in universities and commercial enterprises. The major principle behind structural health claims regulation is that all advertising must be truthful and not misleading, and advertisers must have substantiation for all objective advertising claims before the claims are disseminated. The Commission normally requires an advertiser to have competent and reliable scientific evidence. Among the health claims approved for AstaPure are claims supporting cardiovascular health, neurological health and the advantage of AstaPure in maintaining a normal oxidant/antioxidant balance.

Sponsored Recommendations

Revolutionizing Healthcare: The Impact of Digitalization in Biopharma Innovation

Biopharma enables an entirely new level of innovation that’s simply not possible in conventional drug development. It’s an approach that can fundamentally change the way healthcare...

Navigating the Automotive Industry's Electric Future

The automotive industry is at a turning point. Bloomberg estimates that by 2040, 54% of new vehicle sales will be electric. And by 2030, we’re looking at 100% of passenger vehicles...

Unified Process Control Brings Operational Clarity

Inland Empire Utilities Agency replaces its SCADA enterprise system with the PlantPAx Distributed Control System and reduces complexity for operators

PlantPAx DCS Improves Operational Reliability

KC Water calls on R.E. Pedrotti to replace obsolete wastewater SCADA solution with a unified Modern Distributed Control System (DCS).